Cytokinetics

News

After rival fails, Cytokinetics could broaden Myqorzo label

Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

News

Cytokinetics' president and chief executive Robert Blum

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy

News

Cytokinetics eyes go-it-alone strategy for aficamten

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financi

News

Cytokinetics prepares to take on BMS’ Camzyos in HCM

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

News

JPM on tenterhooks over Novartis-Cytokinetics merger rumour

With M&A news coming thick and fast on the first day of the JP Morgan Healthcare conference in San Francisco, attendees were left hanging as proceedings closed with no

After rival fails, Cytokinetics could broaden Myqorzo label

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics eyes go-it-alone strategy for aficamten

Cytokinetics prepares to take on BMS’ Camzyos in HCM

As Novartis backs off, Amgen said to be after Cytokinetics

JPM on tenterhooks over Novartis-Cytokinetics merger rumour

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Cytokinetics

Editor's Picks